Squadron Capital Management LLC
Position in ELVN — Enliven Therapeutics, Inc.
CIK 2050709
WESTMONT, IL
Position in ELVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$8,120,000
New position
Shares Held
160,000
first reported quarter
Ownership
0.218%
of shares outstanding
% of Portfolio
2.78%
of 13F equity value
Holder Rank
#65
of 208 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Squadron Capital Management LLC holds $280,459,987 across 30 Biotechnology names. ELVN ranks #11 (2.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RLMD |
Relmada Therapeutics, Inc.
|
7,350,000 | $50,862,000 | |
| 2 | CCCC |
C4 Therapeutics, Inc.
|
7,200,000 | $33,624,000 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
865,000 | $33,475,500 | |
| 4 | KOD |
Kodiak Sciences Inc.
|
500,000 | $19,480,000 | |
| 5 | RLAY |
Relay Therapeutics, Inc.
|
970,000 | $18,148,700 | |
| 6 | ZNTL |
Zentalis Pharmaceuticals, Inc.
|
3,700,000 | $17,945,000 | |
| 7 | EWTX |
Edgewise Therapeutics, Inc.
|
290,000 | $11,782,700 | |
| 8 | MAZE |
Maze Therapeutics, Inc.
|
335,000 | $9,996,400 |
All Filings in ELVN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,120,000 | 160,000 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||